Track topics on Twitter Track topics that are important to you
(Reuters) - Acorda Therapeutics Inc's shares plunged 34 percent on Wednesday after the drugmaker said it had paused enrolling patients in two key trials testing its Parkinson's disease drug following patient deaths.
Original Article: Acorda halts enrollment in Parkinson's trial, shares plungeNEXT ARTICLE
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...